| Business Summary | | Watson
Pharmaceuticals,
Inc.
is
primarily
engaged
in
the
development,
manufacture,
marketing
and
distribution
of
branded
and
off-patent
(generic)
pharmaceutical
products.
Through
internal
product
development
and
synergistic
acquisitions
of
products
and
businesses,
the
Company
has
grown
into
a
diversified
specialty
pharmaceutical
company
that
markets
more
than
28
branded
pharmaceutical
product-lines
and
approximately
140
off-patent
pharmaceutical
products.
The
Company
also
develops
advanced
drug
delivery
systems
designed
to
enhance
the
therapeutic
benefits
of
existing
drug
forms.
The
Company
markets
a
number
of
patented
products,
and
also
markets
certain
trademarked
off-patent
products
directly
to
healthcare
professionals,
which
it
classifies
as
branded
pharmaceutical
products. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Watson
Pharmaceuticals
is
engaged
in
the
development,
production,
marketing
and
distribution
of
both
branded
and
off-patent
pharmaceutical
products.
For
the
six
months
ended
6/30/01,
total
revenues
rose
58%
to
$595.8
million.
Net
income
before
accounting
change
fell
46%
to
$128.7
million.
Results
reflect
increased
sales
of
generic
products
due
to
the
acquisition
of
Schein,
offset
by
lower
gain
on
the
sale
of
Andrx
Common
stock. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Allen Chao, Ph.D., 55 Chairman,
CEO and Pres | $769K | Michael Boxer, 39 Sr.
VP, CFO | 302K | Robert Funsten, 41 Sr.
VP, Gen. Counsel, Sec. | 270K | Donald Britt, 52 Sr.
VP, Quality Assurance | -- | Maria Chow, 46 Sr.
VP, Operations | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|